James M. Frates - Feb 11, 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact for James Frates
Stock symbol
AMLX
Transactions as of
Feb 11, 2022
Transactions value $
$0
Form type
4
Date filed
3/28/2022, 04:30 PM
Previous filing
Apr 26, 2023
Next filing
Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Award $0 +25K $0.00 25K Feb 11, 2022 Common Stock 25K $19.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.